Subtype
Malignant Peripheral Nervous System Neoplasm
CI-CAN-00001163Explore in graph →
20 active trials3 evidence items
- NCIt
- C4961
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001163Explore in graph →
Variants & evidence
6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Vemurafenib | Malignant Peripheral Nerve Sheath Tumor | Predictive | C | Supports Sensitivity Response | — | submitted | EID3788In a malignant peripheral nerve sheath tumor patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient was … (full text at CIViC) PMID 24335681 · Kaplan, 2013 · Open in CIViC | civic |
| NF1 Loss2 | ||||||||
| Bevacizumab + EverolimusCombination | Malignant Peripheral Nerve Sheath Tumor | Predictive | B | Does Not Support Sensitivity Response | 2 | submitted | EID7727Sporadic and Neurofibromatosis Type 1 (NF1) related refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) showed no significant clinical benefit when treated with Everolimus in Combination with … (full text at CIViC) PMID 31427883 · Widemann et al., 2019 · Open in CIViC | civic |
| JQ1 Compound | Malignant Peripheral Nerve Sheath Tumor | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1743BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts PMID 24373973 · Patel et al., 2014 · Open in CIViC | civic |
| PARP1 OVEREXPRESSION1 | ||||||||
| Olaparib | Malignant Peripheral Nerve Sheath Tumor | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID7016The majority of MPNST samples were positive for PARP staining. Overall, moderate to high expression of PARP1 and PARP2 was observed (Table 1)....Overall, treatment continued for 60 d at which point 5 … (full text at CIViC) PMID 26650448 · Kivlin et al., 2016 · Open in CIViC | civic |
| SSX1 Fusion1 | ||||||||
| (diagnostic) | Malignant Peripheral Nerve Sheath Tumor | Diagnostic | B | Supports Positive | 3 | accepted | EID1071In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 75% of the malignant peripheral nerve sheath tumors (MPNSTs) were positive for this event. The study did … (full text at CIViC) PMID 11144931 · O'Sullivan et al., 2000 · Open in CIViC | civic |
| TYK2 Pro1104Ala1 | ||||||||
| (oncogenic) | Malignant Peripheral Nerve Sheath Tumor | Oncogenic | B | Supports Oncogenicity | 2 | submitted | EID9218TYK2 protein overexpression was observed in 60% of MPNST cases using an independently generated tissue microarray, regardless of NF1 status. A total of 3 women and 4 men with NF1-MPNST were studied (m… (full text at CIViC) PMID 27875628 · Hirbe et al., 2017 · Open in CIViC | civic |
Data updated 12 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.